Immunocore Holdings plc (IMCR) — SEC Financial Statements & Analysis

Immunocore Holdings plc (IMCR) is a biological products, (no diagnostic substances) company, incorporated in X0. Immunocore Holdings plc trades on Nasdaq as: IMCR. Immunocore Holdings plc (IMCR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Immunocore Holdings plc carries a market cap of $1.62B, a P/E ratio of -89.54x, a P/B ratio of 3.86x, a P/S ratio of 3.76x, an enterprise value of $1.13B, and an EV/EBITDA multiple of -59.75x. On profitability, it posts a gross margin of 101.10%, an operating margin of -5.24%, a net margin of -4.20%, a Return on Equity (ROE) of -4.47%, and a Return on Assets (ROA) of -1.64%. Per share, it reports EPS of $-0.35, diluted EPS of $-0.35, free cash flow per share of $-0.81, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 20.95% year-over-year, net income growth of -11.02% year-over-year, and EPS growth of -12.20% year-over-year. On the balance sheet, it maintains a current ratio of 4.47x, a quick ratio of 4.15x, working capital of $815.85M, a debt-to-equity ratio of 1.67x, a debt ratio of 0.62, an interest coverage ratio of -1.85x, free cash flow of $-41.15M (TTM), and net debt of $-484.92M. Figures sourced from SEC EDGAR.

Market Cap

$1.62B

P/E TTM

-89.54x

EPS TTM

$-0.35

P/B TTM

3.86x

ROE TTM

-4.47%

ROA TTM

-1.64%

Debt To Equity

1.67x

Free Cash Flow TTM

$-41.15M

Net Revenue TTM Growth 1Y

20.95%

Data as of 2026-06-30 · Source: SEC EDGAR